The webinar will feature presentations from Key Opinion Leaders (KOLs) John D. Sheppard, M.D., M.M.Sc. (Virginia Eye Consultants), Paul M. Karpecki, O.D., F.A.A.O. (Clinical Director of Advanced Ocular Surface Disease at Kentucky Eye Institute), and George W. Ousler III (Senior Vice President of Dry Eye at Ora Clinical) who will discuss the current treatment landscape and unmet medical need in treating patients with dry eye disease.

Additionally the core technology behind Mitotech products will be discussed. The core technology is based on a novel class of small molecules – mitochondria-targeting cardiolipin peroxidation inhibitors. Mitotech’s potential treatment for dry eye disease, Visomitin®, has reached Phase III in the U.S. Visomitin’s mechanism of action addresses the most important clinical needs in dry eye disease: tear quality, cornea/conjunctiva healing rate and inflammation.

A live question and answer session will follow.